ASX healthcare stock rockets 25% on big AI news

This medical device company is aiming to make its offering an indispensable central hub.

| More on:
A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Imricor Medical Systems Inc (ASX: IMR) shares are getting a lot of attention from investors on Thursday.

At the time of writing, the ASX healthcare stock is up 25% to a 52-week high of $1.34.

Why is this ASX healthcare stock rocketing?

Investors have been fighting to get hold of the medical device company's shares after it announced a licensing agreement with Switzerland's ADIS.

ADIS is a software company that has been working with Imricor to build artificial intelligence (AI) modules to integrate into Imricor's NorthStar 3D mapping system.

Today's licensing agreement defines the commercial terms for the selling of the NorthStar AI modules to customers.

And while the NorthStar 3D mapping system and the AI modules are not yet approved for commercial sale, regulatory processes are well progressed. As a result, preparations for planned commercial launches across Europe, the United States, and the Middle East in 2025 are underway.

Under the terms of the agreement, Imricor will offer NorthStar AI modules as software license options to users and share the upfront and ongoing software license revenue with ADIS.

What is the NorthStar 3D mapping system?

NorthStar3D is a mapping and guidance system for magnetic resonance imaging (MRI).

It allows users to control the MRI scanner, receive MR images in real-time from the scanner, display those MR images in 3D, actively track Imricor trackable devices, and create 3D electroanatomical maps that include intracardiac electrogram signals from Imricor's Advantage-MR system.

According to the release, the first AI module the companies are targeting is one for providing automatic heart segmentation capabilities to NorthStar.

Segmentation is the process of creating 3D anatomical shells of heart chambers from standard MRI images. It notes that currently a physician must create the 3D shell segmentations manually, which typically takes about 20 minutes. Automatic segmentation in NorthStar is expected to take just a few seconds and make the process much more convenient for physicians.

Commenting on the agreement, the ASX healthcare stock's chair and CEO, Steve Wedan, said:

We have been working with the highly talented people at ADIS for several years, and last year we cemented our joint development activities to deliver cutting edge AI capabilities to NorthStar. We expect these AI modules to increasingly deliver more and more value from the superior imaging capabilities of MRI to our users through NorthStar.

With today's agreement, we have taken the next step with ADIS to solidify the commercial terms around which we will deliver these capabilities, as we get prepared to launch NorthStar to the market. It is our goal to make NorthStar the indispensable central hub around which any customer's iCMR program is built.

Should you invest $1,000 in Imricor Medical Systems, Inc. right now?

Before you buy Imricor Medical Systems, Inc. shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Imricor Medical Systems, Inc. wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Business people discussing project on digital tablet.
Broker Notes

What are brokers saying about this popular ASX 200 stock after the sell-off?

Is now a good time to invest? Let's see what analysts are saying about this beaten down stock.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Wednesday

Will today be a better day for Aussie investors? Let's find out.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

These ASX 200 shares could rise 25% to 60%

Big returns could be on the cards for buyers of these shares.

Read more »

Warren Buffett
Opinions

With the ASX 200 near record highs, I'm taking Warren Buffett's words to heart

Is it still a good time to invest?

Read more »

A concerned man looking at his laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a tough Tuesday session today.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
52-Week Highs

8 ASX 300 shares hitting new price highs today

New share price records were set despite the broader market trading in the red.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Domino's, Johns Lyng, Polynovo, and Praemium shares are dropping today

These shares are having a tough time on Tuesday. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Nine, Qualitas, Woodside, and Zip shares are storming higher today

These shares are having a strong session on Tuesday.

Read more »